Sepsis Power Hour bundle decreases patient mortality by 45%

Sepsis remains a leading cause of death around the world, but early detection could save patients and costs. Virginia Mason Institute’s “Sepsis Power Hour” bundle, a way of detecting early signs of sepsis and improved the time taken to treat patients, has reduced patient mortality due to sepsis by 45 percent.

The Sepsis Power Hour bundle aims to improve patient and provider outcomes when treating sepsis with early identification and quicker intervention. The solution has been in place since 2011 and has decreased patient mortality by 45 percent, saving Virginia Mason $6,000 in 90-day treatment expenses per patient.

"What has really changed with patients and families is in the numbers,” said Evan Coates, MD, a hospitalist at Virginia Mason. “Our mortality rate has been decreasing year after year for four years straight, and it had plateaued for five years prior to that—a substantial improvement. It's in the numbers—care is better for patients."

Further training of nurses, who are the center point of the solution, was able to decrease the average time it took to deliver the bundle by 54 percent. As a result of the bundle, Virginia Mason has reduced patient discharged to long-term facilities by 15 percent and rapid response team calls decreased by 33 percent.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.